Twist Bioscience (NASDAQ:TWST) Sets New 12-Month High at $53.03

Twist Bioscience Co. (NASDAQ:TWST) reached a new 52-week high during trading on Wednesday . The stock traded as high as $53.03 and last traded at $52.46, with a volume of 799404 shares. The stock had previously closed at $46.98.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Guggenheim started coverage on Twist Bioscience in a report on Tuesday. They issued a “buy” rating and a $53.00 target price for the company. Scotiabank raised their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Barclays increased their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Evercore ISI boosted their target price on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $44.00.

Twist Bioscience Stock Up 12.3 %

The firm has a market capitalization of $3.07 billion, a PE ratio of -15.86 and a beta of 1.78. The company has a 50-day moving average of $37.25 and a 200 day moving average of $35.27.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company’s revenue was up 25.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.06) EPS. As a group, equities analysts anticipate that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,132 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total transaction of $37,061.68. Following the completion of the transaction, the chief executive officer now owns 514,149 shares in the company, valued at $16,833,238.26. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Emily M. Leproust sold 1,132 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the sale, the chief executive officer now owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the completion of the sale, the chief executive officer now directly owns 515,281 shares in the company, valued at $17,272,219.12. The disclosure for this sale can be found here. Insiders sold 14,875 shares of company stock valued at $519,432 in the last quarter. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Federated Hermes Inc. bought a new stake in shares of Twist Bioscience in the third quarter worth $29,000. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the fourth quarter worth approximately $30,000. Headlands Technologies LLC bought a new stake in Twist Bioscience during the first quarter valued at approximately $124,000. International Assets Investment Management LLC increased its holdings in Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after buying an additional 3,907 shares during the last quarter. Finally, Brown Advisory Inc. purchased a new stake in Twist Bioscience during the fourth quarter valued at approximately $225,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.